Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DMB1NE2)

Drug Name	Vixarelimab DMB1NE2
Synonyms	RG6536
Drug Type	Antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

2 Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Idiopathic pulmonary fibrosis	DISZGA69	CB03.4	Phase 1	[1]
Pruritus	DISVH62W	EC90	Phase 1	[2]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05785624) A Two-Cohort, Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of Vixarelimab Compared With Placebo in Patients With Idiopathic Pulmonary Fibrosis and in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease. U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT03816891) A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects With Prurigo Nodularis. U.S.National Institutes of Health.